As tumor cells undergo death following BNCT treatment, they release a series of signaling molecules, such as surface-exposed calreticulin (CRT), secreted ATP, and extracellular HMGB1, which trigger adaptive immune response; this mode of cell death is known as immunogenic cell death (ICD) (129, 130). Here, HMGB1 is linked to neoplasm.